Paul Hudson, born on October 14, 1967, in the United Kingdom, is a distinguished businessman and the current Chief Executive Officer (CEO) of Sanofi, one of the world’s leading pharmaceutical companies. Since his appointment in September 2019, Hudson has been at the forefront of reshaping Sanofi into a modern healthcare powerhouse, dedicated to revolutionizing the practice of medicine and enhancing patient outcomes globally.
Hudson’s extensive career in the healthcare sector has spanned multiple continents, including the United States, Japan, and Europe. Before joining Sanofi, he served as CEO of Novartis Pharmaceuticals from 2016 to 2019, where he played a pivotal role in advancing the company’s mission to deliver innovative therapies and improve access to healthcare. His prior experience also includes key leadership positions at AstraZeneca, where he rose to the rank of President of AstraZeneca US and Executive Vice President for North America. He began his career in sales and marketing at GlaxoSmithKline UK and Sanofi-Synthélabo UK, gaining invaluable experience that would shape his future in the industry
Hudson’s leadership at Sanofi has been marked by a commitment to social impact, placing diversity, equity, and inclusion at the heart of the company’s long-term strategy. Under his guidance, Sanofi has prioritized health and environmental sustainability, working to ensure that breakthrough medicines and vaccines are accessible to people around the world.
Academically, Hudson holds a degree in economics from Manchester Metropolitan University, where he was honored with an honorary Doctor of Business Administration in 2018 for his outstanding contributions to the industry. His educational background is complemented by a diploma in marketing from the Chartered Institute of Marketing, further enhancing his expertise in driving business success.
In addition to his professional achievements, Hudson is known for his dedication to his family. He and his wife, Sandra, have three children, and he is an ardent supporter of Manchester United Football Club, reflecting his passion for both sports and community.
As Hudson continues to lead Sanofi towards its ambitious goals, he remains a prominent figure in the global healthcare landscape, inspiring the next generation of leaders to prioritize innovation and social responsibility in their endeavors. His term is set to expire at the General Meeting in 2026, where his transformative impact on the pharmaceutical industry will undoubtedly be felt for years to come.
